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Background: Promyelocytic leukemia (PML) tumor suppressor gene plays a key role in acute PML pathogenesis but
its involvement in pathogenesis and prognosis of solid cancers has not been defined yet.
Patients and methods: In all, 62 ampullary adenocarcinoma patients who underwent curative surgery between
1996 and 2005 were included. Expression analysis of PML was carried out by immunohistochemical staining and
correlated with disease-free survival (DFS) and overall survival (OS).
Results: In 24 tumor specimens (38.7%), PML was classified as absent, in 16 (25.8%) as focally expressed and in 22
(35.5%) as diffusely expressed. By univariate analysis, DFS was significantly influenced by pathological T stage
(P = 0.03), lymph nodal involvement (P = 0.002), and PML expression (P = 0.001). DFS in patients without PML
expression was 28.0 months versus 45.1 and 75.5 for patients with focal and diffuse expression, respectively. OS in
the group of patients without PML expression, with focal expression, and with diffuse expression was 40, 48, and
77 months, respectively (P = 0.002). By a multivariate analysis, PML expression was the strongest prognostic factor
for DFS (P = 0.003) and the only statically significant prognostic factor for OS (P = 0.009).
Conclusions: Our preliminary data suggest PML as a novel prognostic tool for ampullary cancer patients.
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introduction
Although carcinoma of the ampulla of Vater is an uncommon
entity, it accounts for 20%–40% of the resected cases of all
periampullary neoplasms [1, 2]. Many studies have examined
the outcomes of radically resected ampullary cancer, but most
studies had insufficiently large sample sizes to assess prognostic
factors, and in larger series there remains substantial differences
in the main independent prognostic variables. At present, the
most reliable prognostic variable in resected ampullary cancer is
the presence and number of lymph nodes with metastatic
deposits, and no molecular prognostic factors have been
definitively validated in this disease [3, 4]. Similarly, the
adjuvant therapy for resected ampullary carcinoma is poorly
studied due, in part, to the rarity of the cancer. Case series of
adjuvant chemoradiotherapy, generally infusional fluorouracil
with concurrent radiotherapy [5, 6], achieved median survivals
on the order of 3 years. Furthermore, there is no generally
accepted chemotherapy for those with recurrent or distant
metastatic disease.
Literatures still show few data on the role of clinical,
histopathologic, and molecular factors in predicting length of
survival. More specifically, there are only some interesting data
that report on the role of allelic loss (loss of heterozygosity) of
chromosomes 5q, 17p, and 18q as molecular significant
prognostic markers for ampullary cancer patients [7–9].
Achille et al. [7] reported that chromosome 5 allelic losses
signify early events in tumors of the papilla of Vater. Moreover,
Scarpa et al. [8] evaluated the prognostic role of loss of
heterozygosity on chromosomes 17p and 18q in a cohort of
53 ampullary cancers [9].
More recently, Santini et al. [10] reported a positive statistically
significant correlation between survival and Cox-2 in ampullary
cancer patients These data suggest that, in ampullary
carcinoma, Cox-2 may play a relevant role in determining the
biological phenotype and the aggressiveness of tumor.
A novel molecular marker candidate for human cancer
pathogenesis and progression, promyelocytic leukemia (PML),
is a tumor suppressor gene implicated in the pathogenesis of
leukemia and human cancers [11]. PML belongs to a large
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family of proteins harboring a distinct zinc finger domain
designated the RING finger [12].
The PML protein is typically concentrated in subnuclear
structures, known as PML nuclear bodies. In the vast majority
of acute promyelocytic leukemia patients, PML is fused to the
retinoic acid receptor a (RARa) gene as a consequence of
chromosomal translocation [13]. The PML-RARa protein
inhibits RARa transcriptional function, and physically
associates with PML, leading to its delocalization from
nuclear bodies and consequently deregulation of the functions
of PML and nuclear bodies. Recent studies suggest that PML
and PML nuclear bodies play a role in the regulation of
apoptosis, growth and DNA repair, in addition to tumor
suppression and transcription [13].
PML colocalizes with >30 different proteins, including p53,
pRb, Daxx, Sp100, cAMP-responsive element-binding protein,
and small ubiquitin-related modifier protein-1 [14–16].
PML protein expression is reduced or abolished in various
human malignancies, including carcinomas of the prostate,
colon, breast, and lung, as well as lymphomas, CNS tumors,
and germ-cell tumors [17].
Furthermore, loss of PML expression is associated with
tumor progression in prostate, breast, gastric, and CNS
cancers [17, 18], even if inconclusive data have been reported
about the impact on survival. However, the clinicopathological
significance of PML expression in ampullary cancer is not
yet established.
In order to investigate the potential role of PML in this
disease, we retrospectively analyzed the immunohistochemical
expression of PML in a very homogenous cohort of patients
treated with radical surgery.
patients and methods
clinical data and tumor specimen acquisition
This retrospective study was restricted to patients with ampullary
carcinoma consecutively treated at the Catholic University School of
Medicine of Rome and at the University Campus Bio-Medico of Rome
from 1986 to 2006. To be eligible for this analysis, each subject underwent
surgical resection for tumors of ampullary origin with curative intent, and
only patients without known residual disease were analyzed. All patients
were staged before surgery by clinical examination, computed tomography
of the thorax, abdomen, and pelvis, and, when indicated, intraoperative
ultrasound of the liver, excluding the presence of overt distant metastases.
Data on clinical variables, including sex, age, preoperative assessment of
disease state, and type of operative procedure, were gathered retrospectively
from patient records. All specimens underwent gross anatomical
examination according to the procedure described by Rosai [19] including
evaluation of all anatomic structures (pancreatic duct, ampulla of Vater,
common bile duct, and pancreatic head). All tumors included in the study
were limited to the ampulla or were primarily located in the ampulla and
secondarily spreading into the neighboring structures. Pathological findings
(tumor size and spread, and lymph node status) were obtained from the
pathologists’ original reports. In addition to the original pathological
reports, tumor–node–metastasis status classification was reassessed as
International Union Against Cancer [20]. Overall survival (OS) was
determined from the date of initial surgery to the date of death or the last
contact. Disease-free survival (DFS) was defined as the interval between the
initial surgery and the documented disease representation. Follow-up data
were available for all included patients. The study was carried out with
approval of the relevant local institutional research boards.
immunohistochemistry
Representative tumor blocks were sectioned at 3-lm thickness for
immunohistochemical studies. Immunohistochemistry was carried out by
the streptoavidin–biotin method. Endogenous peroxidase in the section
was blocked by incubating them in 3% hydrogen peroxide. The used
antibody was a rabbit polyclonal antibody against PML protein (clone
PG-M3, Santa Cruz Biotechnology, Inc.) at 1:50 dilution. This antibody has
been used and validated previously by others [17, 21]. Sections were
incubated with LSAB2 (Dakocytomation). 3-3#-diaminobenzidine was used
for color development and hematoxylin was used for counterstaining.
Negative control slides processed without primary antibody were included
for each staining. Slides were examined without knowledge of the
corresponding clinicopathologic data.
Immunostaining was considered positive if appropriate brown staining
was seen in tumor cell. PML expression was established calculating the
percentage of nuclear immunoreactive cells in a total of 1000 neoplastic
cells.
scoring and quantification of the immunoreactivity
In terms of PML immunohistochemical staining results, all cases were
divided into complete loss (nuclear immunoreactivity in <10% of tumor
cells), focal positivity (in ‡10% or more but <50%), and diffuse positivity
(in ‡50%), as previously reported by Lee et al. [18].
statistical analysis
Standard descriptive analysis was used to describe patients’ features. The v2
test or Fisher’s exact test (two sided) was used for searching possible
correlations between PML expression status in the gastric carcinomas
and clinicopathological parameters.
Univariate survival analysis for each prognostic variable on OS was
estimated according to the Kaplan–Meier method [22]. The terminal event
was death attributable to cancer or noncancer causes. The statistical
significance of the differences in survival distribution among the prognostic
groups was evaluated by the log-rank test [23]. The Cox proportional
hazards model was applied to the multivariate survival analysis [24].
P value <0.05 was regarded as statistical significant in two-tailed tests.
SPSS software (version 14.00, SPSS, Chicago, IL) was used for statistical
analysis.
results
patient characteristics
The main clinicopathological features are summarized in
Table 1. The cohort consisted of 62 patients with pathological
diagnosis of radically resected cancer of the ampulla (34 men
and 28 women). The median age at diagnosis was 59 years
(range 38–82). Twelve patients (19.3%) were classified as T1, 24
(38.7%) as T2, 22 (35.5%) as T3, and only four (6.5%) as T4.
Twenty-one (63.13%) patients had locoregional lymph node
metastasis. Adjuvant radiotherapy and/or chemotherapy for
ampullary cancer were not routinely offered in the hospitals
involved in the study. The median duration of follow-up after
surgery was 66 months (range 6–118 months). The median OS
was 64 months (range 6–98). The 1-, 3-, and 5-year OSs were
85.5%, 51.6%, and 33.8%, respectively.
PML staining in normal and cancer tissues
PML immunostaining showed an intense nuclear
immunoreactivity of the normal ampullary epithelia in all 62
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tissues examined (Figure 1A). PML displayed a nuclear
speckled staining pattern compatible with its normal
localization in the PML nuclear body. In some instances,
a concomitant diffuse nucleoplasmic immunostaining was
found. By contrast, in tumor specimens, PML staining was
frequently focally or completely lost. In particular, of the 62
tissue samples, in 24 (38.7%) ampullary adenocarcinomas PML
was classified as absent (1B), in 16 (25.8%) as focally expressed
(1C), and in the other 22 (35.5%) as diffusely expressed (1D).
Endothelial cells and tumor-infiltrating lymphocytes were
strongly positive for PML expression in both normal and tumor
tissues, thus serving as internal positive controls.
PML expression and clinicopathological variables
PML immunostaining was correlated with all
clinicopathological parameters. The only parameters that
resulted to be negatively correlated with PML were the
pathological ones. In particular, PML downregulation was
correlated with T-stage increase with a P value of 0.004, with
lymph nodal involvement with a P value of 0.001 and with
tumor grading increase with a P value of 0.03. In addition, no
differences of PML expression were recorded between patients
of different ages and gender.
univariate analysis of survival
To determine the prognostic impact of PML downregulation,
all the cases were classified as absent expression, focal
expression, and diffuse expression of PML as previously
reported.
By univariate analysis, DFS in our cohort of patients was
influenced significantly by pathological T stage, lymph nodal
involvement, and PML expression. In particular, DFS in
patients without PML expression was 28.0 [95% confidence
interval (CI) 24.13–31.86] months versus 45.1 (95% CI
24.77–65.22) and 75.5 (95% CI 62.75–91.24) for patients with
focal and diffuse expression, respectively (P = 0.0001). The
median DFS in patients with T1–2 tumors was 59.40 versus
34.00 in patients with T3–4 tumors (P = 0.03). Moreover,
median DFS was longer in patients with lymph nodal
involvement than DFS recorded in patients without (61.00
versus 31.50, P = 0.002). All the data regarding the univariate
analysis of DFS are summarized in Table 2 and Kaplan–Meier
curves according to PML expression plotted in Figure 2.
Concerning OS, PML expression represents in our
population a statistically significant prognostic factor together
with lymph nodal involvement. OS in the group of patients
without PML expression, with focal expression and with diffuse
expression was 40.00 (95% CI 28.95–49.04), 48.00 (95% CI
31.80–68.19), and 77.00 (95% CI 55.97–88.02) months,
respectively (P = 0.002). In addition, median OS was shorter in
patients with lymph nodal involvement than this documented
in patients without (74.25 versus 42.00) (P = 0.007). The data
about OS are presented in Table 3 and Kaplan–Meier curves
according to PML expression plotted in Figure 3.
multivariate analysis of survival
By a multivariate Cox regression analysis, PML expression was
the strongest prognostic factor for DFS (P = 0.003) and the
only statically significant prognostic factor for OS (P = 0.009).
The calculated relative risk of disease progression in
ampullary cancer patients with focal PML expression was 0.464
(95% CI 0.333–0.668) and this in patients with diffuse PML
expression was 0.217 (95% CI 0.178–0.477). The other
pathological parameter that continued to be a statistically
significant prognostic factor for DFS was the lymph nodal
involvement (P = 0.004).
In addition, PML expression was the only parameter that
represented a prognostic significant factor also in multivariate
analysis (P = 0.009). The relative risk of death in ampullary
cancer patients with focal PML expression was 0.593 (95%
CI 0.401–0.863) and this in patients with diffuse PML
expression was 0.359 (95% CI 0.259–0.562).
The results of the multivariate analysis for DFS and OS
are summarized in Tables 4 and 5.
discussion
There is a need for a better understanding of the biology of
ampullary adenocarcinoma, the identification of potential
prognostic factors, and clinically relevant molecular targets for
therapy.
There are few substantial data reporting significant
prognostic markers for ampullary cancer patients. The
influence of pathological (tumor size, lymph node involvement,
status of resection margins, and perineural invasion) [3],
surgical (aggressive surgical approach versus limited resection)
[25], and biological (p53, c-erbB2, bax-2, mapsin, and
apoptotic index) factors is not clear [26, 27].
Table 1. Patient’s features
Total no. of patients 62
Median age (range) 59 (range 38–82) years
Gender
Male versus female 34 versus 28
(54.8% versus 45.2%)
Pathological T stage
1 12 (19.3%)
2 24 (38.7%)
3 22 (35.5%)
4 4 (6.5%)
Pathological lymph nodal involvement
Assent (N0) 41 (66.13%)
Present (N+) 21 (33.9%)
Grading
G1 18 (29.0%)
G2 28 (45.2%)
G3 6 (9.7%)
Promyelocytic leukemia expression
Absent 24 (38.7%)
Focal 16 (25.8%)
Diffuse 22 (35.5%)
One-year OS rate 53 (85.5%)
Three-year OS rate 32 (51.6%)
Five-year OS rate 21 (33.8%)
Median OS (median, range) 64 (6–98) months
OS, overall survival.
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An increasing interest is focused on new molecular markers
to select patients with better prognosis and, therefore, in need
of more aggressive treatments.
Recently, Santini et al. [10] reported that Cox-2 expression is
a poor prognostic factor for patients with cancer of the ampulla
of Vater and may represent a possible and appropriate target
for novel targeted therapies. However, in medical literature,
there are controversial data about the prognostic role of Cox-2
in ampullary carcinoma patients. Kim et al. [28] have
investigated the prognostic role of Cox-2 overexpression in
ampullary cancer but failed to show any correlation with
survival and other clinicopathologic factors. On the basis of
these counteracting results, no further studies were carried out
to elucidate the potential role con Cox-2 as a target for therapy
in ampullary cancer patients.
Some other interesting data about molecular aspects of
ampullary cancer have been published by Santini et al. [29].
The authors clearly showed that high immunohistochemical
staining for the human equilibrative nucleoside transporter 1
(hENT1) is significantly correlated with poor prognosis in
patients with resected cancer of the ampulla of Vater. Given the
positive association between hENT1 protein and benefit from
gemcitabine in pancreatic cancer, this population might
particularly derive benefit from gemcitabine-based therapy.
As already stated, PML seems to have an important role in
solid cancer, both in tumorigenesis and progression. Gurrieri
et al. [17] demonstrated that although PML was more
frequently completely lost in advanced cancers, it was also lost
in early stages of tumorigenesis. This observation raises the
Figure 1. Promyelocytic leukemia (PML) immunostaining. (A) PML immunostaining in peritumoral normal epithelia cells; (B) absent PML
immunostaining in ampullary adenocarcinoma cells; (C) focally expressed PML immunostaining in ampullary adenocarcinoma cells; and (D) diffusely
expressed PML immunostaining in ampullary adenocarcinoma cells.
Table 2. Univariate analysis of DFS in radically resected ampullary
cancer patients
Median
DFS
(months)
95%
confidence
interval
P value
Gender
Male 44.90 35.90–78.93 0.976
Female 51.20 39.21–67.90
Age
<65 years old 49.00 34.72–65.91 0.656
>65 years old 55.60 39.4–69.56
Pathological T stage
T1–2 59.40 37.11–79.44 0.03
T3–4 34.00 24.38–49.36
Pathological lymph
nodal involvement
N0 61.00 35.56–74.70 0002
N+ 31.50 23.56–44.93
Grading
G1 54.30 41.94–62.11 0.160
G2 45.70 35.22–61.02
G3 42.20 28.56–59.30
Promyelocytic leukemia
expression
Absent 28.00 24.13–31.86 0.001
Focal 45.10 24.77–65.22
Diffuse 75.50 62.75–91.24
DFS, disease-free survival.
Bold indicates statistically significative differences.
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question of whether PML loss is an important event in tumor
initiation and/or progression. The ability of PML to control
proliferation following oncogenic stimulation and apoptosis in
cells experiencing DNA damage or other proapoptotic stimuli
provides a straightforward explanation for how loss of PML
protein would favor tumor initiation. This hypothesis has been
demonstrated for lymphoma and other hemopoietic
malignancies, in which the survival advantage conferred to
cancer cells by PML loss could be a critical determinant in
oncogenesis. However, PML loss could also favor tumor
initiation in non-hemopoietic malignancies.
On this basis, we design this study to investigate for the first
time in literature the role of PML suppression in ampullary
carcinoma patients. Our findings suggest, for the first time in
literature, that PML downregulation may play an important
role in pathogenesis and progression of ampullary carcinoma as
already demonstrated for other solid cancer histotype.
Moreover, in our population, PML seems to play also a central
role in the determination of prognosis both in terms of DFS
and OS. As a consequence, PML could represent an ideal target
for anticancer therapy for patients affected by this disease and
Figure 2. Kaplan–Meier survival plot for disease-free survival in radically
resected ampullary cancer patients according to promyelocytic leukemia
expression.
Table 3. Univariate analysis of overall survival in radically resected
ampullary cancer patients
Median
disease-free
survival
(months)
95%
confidence
interval
P value
Gender
Male 59.90 38.21–67.90 0.451
Female 70.20 25.90–78.93
Age
<65 years old 61.02 31.25–71.93 0.737
>65 years old 66.90 39.89–77.89
Pathological T stage
T1–2 67.32 43.56–78.23 0.231
T3–4 53.50 31.00–64.45
Pathological lymph
nodal involvement
N0 74.25 45.65–85.56 0.007
N+ 42.00 24.76–48.76
Grading
G1 67.32 39.09–83.28 0.104
G2 59.77 40.45–76.36
G3 51.23 24.67–59.93
Promyelocytic leukemia expression
Absent 40.00 28.95–49.04 0.002
Focal 48.00 31.80–68.19
Diffuse 77.00 55.97–88.02
Bold indicates statistically significative differences.
Figure 3. Kaplan–Meier survival plot for overall survival in radically
resected ampullary cancer patients according to promyelocytic leukemia
expression.
Table 4. Multivariate analysis of disease-free survival in radically
resected ampullary cancer patients
Relative
risk of
progression
95%
confidence
interval
P
Pathological T stage
T1–2 1 – 0.356
T3–4 0.815 0.467–1.961
Pathological lymph nodal involvement
N0 1 – 0.040
N+ 0.371 0.390–0.976
Promyelocytic leukemia expression
Absent 1 – 0.003
Focal 0.464 0.333–0.668
Diffuse 0.217 0.178–0.477
Bold indicates statistically significative differences.
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that actually receive only very modest benefit from the available
treatments.
In addition, Lee et al. [18], in order to investigate the
mechanism of PML protein loss, analyzed PML messenger RNA
(mRNA) levels by RT-PCR and found that PML mRNA levels
were similar in all gastric carcinoma cell lines regardless of PML
protein level. These findings prompted the authors to state that
a posttranslational proteasomal degradation mechanism
underlies the loss of PML protein. Moreover, a proteasome-
dependent pathway has been previously proposed for the loss of
PML protein [30] and the results of our proteasome inhibitor
experiment suggest that a proteasome-dependent pathway is
responsible for PML protein loss in the gastric carcinoma cell
lines. On this basis, the present data could represent the
rationale to investigate if a proteasome-dependent pathway is
responsible of PML degradation also in ampullary cancer and if
confirmed this hypothesis, a proteasome inhibitor, could
represent an attractive therapeutic option to test in this
patients’ population.
In conclusion, our data clearly define PML as a prognostic
factor for ampullary cancer patients and this could represent
a parameter to indicate which patients need to receive a more
aggressive therapeutic approach after surgery.
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